News about

EMA Enhances Scientific Advice Process for Medicines Targeting Public Health Threats

EMA Enhances Scientific Advice Process for Medicines Targeting Public Health Threats

Under the new system, medicine developers can receive joint scientific advice from EMA and national clinical and ethics experts. This coordinated approach aligns trial and regulatory requirements early, helping accelerate trial approvals and access to critical medicines.

| 18/11/2025 | By 361

Vanda's Tradipitant Shows Strong Efficacy in Preventing Wegovy-Induced Nausea and Vomiting

Vanda's Tradipitant Shows Strong Efficacy in Preventing Wegovy-Induced Nausea and Vomiting

Vanda Pharmaceuticals has announced positive topline results from its randomised controlled study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for preventing nausea and vomiting associated with GLP-1 receptor agonist Wegovy in overweight and obese adults.

| 18/11/2025 | By 349

CPHI & PMEC India 2025 to Spotlight Global Pharma Innovation, Sustainability and Collaboration

CPHI & PMEC India 2025 to Spotlight Global Pharma Innovation, Sustainability and Collaboration

Set to take place from 25–27 November 2025 at India Expo Mart, Greater Noida, Delhi, the 18th edition of CPHI & PMEC India 2025 will bring together over 2,000 exhibitors and 35,000 plus industry professionals.

| 18/11/2025 | By 994

Gericke Launches GUC-F Universal Controller for Precision Feeding and Dosing

Gericke Launches GUC-F Universal Controller for Precision Feeding and Dosing

The Gericke GUC-F Universal Controller delivers precise, reliable control for feeding, dosing, batching, and weighing. It combines industrial robustness with the connectivity and flexibility demanded by modern powder handling applications.

| 18/11/2025 | By 173

Alembic Pharmaceuticals Receives USFDA Final Approval for Diltiazem Hydrochloride Tablets

Alembic Pharmaceuticals Receives USFDA Final Approval for Diltiazem Hydrochloride Tablets

Alembic Pharmaceuticals has received final approval from the USFDA for its Diltiazem Hydrochloride Tablets in multiple strengths, a generic version of Cardizem used for managing certain types of angina. The approval adds to the company’s growing US portfolio, bringing its total ANDA count to 230, including 210 final and 20 tentative approvals.

| 18/11/2025 | By 207

PharmNXT Biotech Bags 'Top Emerging Biotech Company' Award for Sustainable SUT Innovation

PharmNXT Biotech Bags 'Top Emerging Biotech Company' Award for Sustainable SUT Innovation

PharmNXT Biotech, a fast-growing biotechnology company specialising in sustainable single-use technologies (SUTs), has been named the ‘Top Emerging Biotech Company’ at the BioSpectrum India Excellence Awards 2025.

| 18/11/2025 | By 488

Airpharm Partners with Sensos to Introduce AIoT-Driven Pharmaceutical Logistics

Airpharm Partners with Sensos to Introduce AIoT-Driven Pharmaceutical Logistics

Airpharm Pharma Logistics, a European leader in pharmaceutical logistics and temperature-controlled transport, has entered into a strategic partnership with Sensos, the pioneer of the AIoT Supply Chain System of Action.

| 18/11/2025 | By 189

AstraZeneca, Sun Pharma Announce Second Brand Partnership to Expand Access to Hyperkalaemia Treatment in India

AstraZeneca, Sun Pharma Announce Second Brand Partnership to Expand Access to Hyperkalaemia Treatment in India

AstraZeneca and Sun Pharma have entered into a second exclusive brand partnership to expand access to Sodium Zirconium Cyclosilicate (SZC) in India for the management of Hyperkalaemia.

| 17/11/2025 | By 708

Marksans Pharma's UK Arm Relonchem Receives UK MHRA Approval for Mefenamic Acid Tablets

Marksans Pharma's UK Arm Relonchem Receives UK MHRA Approval for Mefenamic Acid Tablets

Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for mefenamic acid 250 mg and 500 mg film-coated tablets. The approval further expands Relonchem’s growing footprint in the UK generics market.

| 17/11/2025 | By 334

EMA Recommends EU Approval for Waskyra to Treat Wiskott-Aldrich Syndrome

EMA Recommends EU Approval for Waskyra to Treat Wiskott-Aldrich Syndrome

The EMA has recommended EU marketing authorisation for Waskyra (etuvetidigene autotemcel), a gene therapy for patients aged six months and older with Wiskott-Aldrich Syndrome (WAS). The treatment uses a patient’s own modified stem cells to restore functional WAS protein.

| 17/11/2025 | By 285

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members